Global Perspectives on Leukemia in 2022 and Beyond
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia.
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
FACULTY MEMBERS
Aaron Logan, MD, PhD
University of California San Francisco, CA, USA
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Charles Mullighan, MD, FRACP, MBBS
St. Jude Children’s Research Hospital, Memphis, TN, USA
Naval Daver, MD, FRACP, MBBS
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Rami Komrokji, MD
H. Lee Moffitt Cancer Center, Tampa, FL, USA
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, France
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- MDS: Low-Risk Disease
- MDS: High-Risk Disease
- ALL: Genetic Subsets
- ALL: Role of Monoclonal and Bispecific Antibodies
- AML: Newly Diagnosed Patients (including FLT3– and IDH1/2-mutated disease)
- AML: Relapsed/Refractory Patients (including FLT3– and IDH1/2-mutated disease)
- The Current and Future Roles of Transplantation in Leukemias
